- Home
- QIPT vs HLVX Comparison
QIPT vs HLVX Comparison
Compare QIPT & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- HLVX
- Stock Information
- Founded
- QIPT 1993
- HLVX 2020
- Country
- QIPT United States
- HLVX United States
- Employees
- QIPT N/A
- HLVX N/A
- Industry
- QIPT
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- HLVX Health Care
- Exchange
- QIPT Nasdaq
- HLVX Nasdaq
- Market Cap
- QIPT 92.2M
- HLVX 83.7M
- IPO Year
- QIPT N/A
- HLVX 2022
- Fundamental
- Price
- QIPT $1.78
- HLVX $2.06
- Analyst Decision
- QIPT Buy
- HLVX Hold
- Analyst Count
- QIPT 2
- HLVX 5
- Target Price
- QIPT $2.85
- HLVX $2.33
- AVG Volume (30 Days)
- QIPT 614.3K
- HLVX 454.3K
- Earning Date
- QIPT 08-13-2025
- HLVX 08-07-2025
- Dividend Yield
- QIPT N/A
- HLVX N/A
- EPS Growth
- QIPT N/A
- HLVX N/A
- EPS
- QIPT N/A
- HLVX N/A
- Revenue
- QIPT $240,848,000.00
- HLVX N/A
- Revenue This Year
- QIPT $3.35
- HLVX N/A
- Revenue Next Year
- QIPT $5.39
- HLVX N/A
- P/E Ratio
- QIPT N/A
- HLVX N/A
- Revenue Growth
- QIPT N/A
- HLVX N/A
- 52 Week Low
- QIPT $1.35
- HLVX $1.34
- 52 Week High
- QIPT $4.07
- HLVX $14.43
- Technical
- Relative Strength Index (RSI)
- QIPT 44.77
- HLVX 63.20
- Support Level
- QIPT $1.75
- HLVX $1.99
- Resistance Level
- QIPT $2.18
- HLVX $2.12
- Average True Range (ATR)
- QIPT 0.09
- HLVX 0.08
- MACD
- QIPT -0.02
- HLVX 0.02
- Stochastic Oscillator
- QIPT 17.54
- HLVX 80.33
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.